EMEA-000478-PIP02-18

Key facts

Active substance
navitoclax
Therapeutic area
Oncology
Decision number
P/0255/2018
PIP number
EMEA-000478-PIP02-18
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of myelofibrosis
Route(s) of administration
Oral use
Contact for public enquiries
AbbVie Ltd

E-mail: paediatricteam@abbvie.com
Tel. +44 (0)1628 408248

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating